A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer
Authors:
Open Access
- 11 October 2011
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 23 (6) , 1441-1448
Abstract
Eribulin mesylate is a non-taxane microtubule dynamics inhibitor that recently gained Food and Drug Administration approval for late-line metastatic breast cancer (MBC). In this single-arm, multicentre open-label phase II trial Japanese patients pretreated with an anthracycline and a taxane received 1.4 mg/m2 eribulin mesylate (2- to 5-min i.v. infusion on days 1 and 8 of a 21-day cycle). The primary efficacy end point was overall response rate (ORR) by independent review. Patients (N = 80) had received a median of three prior chemotherapy regimens (range 1–5). ORR was 21.3% [95% confidence interval (CI) 12.9–31.8; all partial responses (PRs)], stable disease (SD) occurred in 30 patients (37.5%) and the clinical benefit rate (complete response + PR + SD ≥6 months) was 27.5% (95% CI 18.1–38.6). Median duration of response was 3.9 months (95% CI 2.8–4.9), progression-free survival was 3.7 months (95% CI 2.0–4.4) and overall survival was 11.1 months (95% CI 7.9–15.8). The most frequent treatment-related grade 3/4 adverse events were neutropenia (95.1%), leukopenia (74.1%) and febrile neutropenia (13.6%). Grade 3 peripheral neuropathy occurred in 3.7% of patients (no grade 4). Eribulin exhibited efficacy and tolerability in Japanese patients with heavily pretreated MBC.Keywords
Funding Information
- Eisai Inc
This publication has 24 references indexed in Scilit:
- Ixabepilone, a New Treatment Option for Metastatic Breast CancerAmerican Journal of Clinical Oncology, 2010
- Eribulin Binds at Microtubule Ends to a Single Site on Tubulin To Suppress Dynamic InstabilityBiochemistry, 2009
- A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid MalignanciesClinical Cancer Research, 2009
- Treatment Options for Breast Cancer Resistant to Anthracycline and TaxaneMayo Clinic Proceedings, 2009
- Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphaseMolecular Cancer Therapeutics, 2008
- Achievements in Systemic Therapies in the Pregenomic Era in Metastatic Breast CancerThe Oncologist, 2007
- Overview of Resistance to Systemic Therapy in Patients with Breast Cancer2007
- The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growthMolecular Cancer Therapeutics, 2005
- A phase I pharmacokinetic and target validation study of the novel anti-tubulin agent E7389: A California Cancer Consortium trialJournal of Clinical Oncology, 2005
- Induction of Morphological and Biochemical Apoptosis following Prolonged Mitotic Blockage by Halichondrin B Macrocyclic Ketone Analog E7389Cancer Research, 2004